Why Royal Dutch Shell Plc, AstraZeneca plc and Aggreko plc Should Lag The FTSE 100 Today

Royal Dutch Shell Plc (LON: RDSB), AstraZeneca plc (LON: AZN) and Aggreko plc (LON: AGK) all slide.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 (FTSEINDICES: ^FTSE) is continuing its positive week, up another 21 points to 6,642 approaching midday for a gain of 87 points on the week so far. Today the index had been affected by mixed earnings reports, but has been buoyed by generally positive noises from the US Federal Reserve yesterday — growth is uncertain, but inflation is still low. The latest Chinese manufacturing figures remain upbeat too.

But which of today’s updates have held back the FTSE? Here are three that resulted in share price falls:

Royal Dutch Shell

Shares in Royal Dutch Shell slumped 115p (5%) to 2,204p this morning after first-half earnings, on a current cost of supplies (CCS) basis, fell 20% to $3.6bn — for Q2 itself, earnings crashed to $2.4bn from $6bn in the same quarter last year. Basic earnings per share (EPS) for the quarter, again at CCS, fell 21%, though the Q2 dividend was lifted 5% to 45 cents per ordinary share.

Chief executive Peter Voser said “Higher costs, exploration charges, adverse currency exchange rate effects and challenges in Nigeria have hit our bottom line. These results were undermined by a number of factors – but they were clearly disappointing for Shell“.

AstraZeneca

AstraZeneca reported a 4% fall in second-quarter revenue, to $6.23bn, with loss of exclusivity on several drugs knocking an estimated $500m off sales. Adjusted pre-tax profit for quarter fell 10% at constant exchange rates, with adjusted EPS down 21% to $1.20. For the half, pre-tax profit slipped 16% with EPS also down 21%.

The fall-off in revenue from traditional drugs was largely anticipated, and with plans for the future underway chief executive Pascal Soriot told us that “We continue to invest in distinctive science, our pipeline projects, products and key markets and our five key growth platforms delivered a double-digit increase in revenue contribution“.

Aggreko

Aggreko shares fell 105p (5.8%) to 1,676p, also on the release of second-half figures. In this case, the provider of power and temperature control equipment reported a rise in revenue, of 4% to £760m, but pre-tax profit slipped by 2% to £146m with EPS dropping 4% to 39.94p. At least the dividend was up, by 10% to 9.11p per share — a similar rise in the final dividend would give shareholders a modest 1.6% yield.

Despite these poorer-than-expected first-half figures, chief executive Rupert Soames seemed upbeat, saying “Our expectations for the full year remain unchanged“. The City is currently forecasting an 8% fall in EPS, with the shares on a forward P/E of 19.

Finally, reliable dividends can more than compensate for the day-to-day ups and downs of share prices. So how about a company that’s offering a 5% yield and which could be set for some nice share price appreciation too?

It’s the subject of our BRAND-NEW report, “The Motley Fool’s Top Income Share For 2013“, which you can get completely free of charge — but it will only be available for a limited period, so click here to get your copy today.

> Alan does not own any shares mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »